HALO
NASDAQ
US
Halozyme Therapeutics, Inc. - Common Stock
$64,49
▼ $-0,91
(-1,39%)
Vol 1.5M
12
Skor Kualitas
ok
Pemeriksaan Mendalam
2/5
ok
Pendapatan ✓
Laba Bersih ✓
>IPO ✗
Kap. Pasar
$7.9B
P/E
13,3
ROE
141,6%
Margin
47,9%
D/E
299,80
Beta
0,97
52W
$47–$80
Konsensus Wall Street
15 analis · Apr 20262
Beli Kuat
9
Beli
3
Tahan
1
Jual
0
Jual Kuat
73,3%
Peringkat Beli
Grafik Harga
Saham Serupa
Pendapatan
Tingkat beat: 75,0%| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Des 2025 | $2,24 | $-0,24 | $-2,48 |
| Sep 2025 | $1,66 | $1,72 | +$0,06 |
| Jun 2025 | $1,29 | $1,54 | +$0,25 |
| Mar 2025 | $0,97 | $1,11 | +$0,14 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Pendapatan | — | $298.0M | $264.9M | $325.7M | $354.3M | $451.8M |
| Laba Bersih | — | $137.0M | $118.1M | $165.2M | $175.2M | -$141.6M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 136.6% | 136.6% | 136.6% | 136.6% | 141.6% | 141.6% |
| P/E (TTM) | 11.50 | 14.64 | 15.81 | 13.68 | 13.14 | 13.29 |
| Net Margin | 50.7% | 47.3% | 47.3% | 47.3% | 47.9% | 47.9% |
| Gross Margin | 85.8% | 84.2% | 84.2% | 84.2% | 84.5% | 84.5% |
| D/E Ratio | 453.53 | 453.53 | 453.53 | 453.53 | 299.80 | 299.80 |
| Current Ratio | 8.36 | 8.36 | 8.36 | 8.36 | 1.59 | 1.59 |
Rasio Utama
ROA (TTM)
27,9%
P/S (TTM)
6,37
P/B
16,7
EPS (TTM)
$4,76
CF/Share
$2,37
Pertumbuhan Pendapatan 3T
+31,8%
52W High
$79,50
52W Low
$46,76
$46,76
Rentang 52 Minggu
$79,50
Kesehatan Keuangan
Arus Kas Bebas
-$70.2M
Utang Bersih
$2.0B
Kas
$133.8M
Total Utang
$2.1B
Per tanggal Des 31, 2025
Як HALO виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка HALO vs аналоги Biotechnology
P/E
13,3
▼
29%
di bawah
rekan
(18,8)
vs Rekan
vs Industri
Undervalued
P/S
6,4
▼
50%
di bawah
rekan
(12,9)
vs Rekan
vs Industri
Undervalued
P/B
16,7
▲
580%
di atas
rekan
(2,5)
vs Rekan
vs Industri
Overvalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість HALO vs аналоги Biotechnology
ROE
141,6%
▲
310%
di atas
rekan
(-67,3%)
vs Rekan
vs Industri
Tingkat atas
Net margin
47,9%
▲
117%
di atas
rekan
(-286,8%)
vs Rekan
vs Industri
Di bawah rata-rata
Валова маржа
84,6%
▲
8%
di atas
rekan
(78,6%)
vs Rekan
vs Industri
Lemah
ROA
27,9%
▲
160%
di atas
rekan
(-46,7%)
vs Rekan
vs Industri
Tingkat atas
Фінансове здоровʼя HALO vs аналоги Biotechnology
D/E ratio
299,8
▼
0%
di bawah
rekan
(0,0)
vs Rekan
vs Industri
Utang tinggi
Поточна ліквідність
1,6
▼
64%
di bawah
rekan
(4,4)
vs Rekan
vs Industri
Likuiditas rendah
Beta
1,0
▼
0%
di bawah
rekan
(1,0)
vs Rekan
vs Industri
Kurang volatil
Радар фундаменталів HALO
HALO
Median rekan
Industri
HALO прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
HALO vs аналоги: ключові метрики
Opini AI Terbaru
Grok
BUY
Price action shows a significant pullback from the February 2026 high of $82.22 to the current $64.19, representing about a 22% dip, which appears to be testing support around $62-64 seen in prior lows, making this a potentially attractive entry …
Mar 23, 2026Berita Terbaru
Belum ada berita terkait